1. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
- Author
-
Hong W, Wang K, Zhang YP, Kou JY, Hong D, Su D, Mao WM, Yu XM, Xie FJ, and Wang XJ
- Subjects
- Adult, Aged, Antimetabolites, Antineoplastic therapeutic use, Carcinoma, Non-Small-Cell Lung epidemiology, China epidemiology, Deoxycytidine therapeutic use, Female, Genetic Markers genetics, Genetic Predisposition to Disease epidemiology, Genetic Predisposition to Disease genetics, Humans, Lung Neoplasms epidemiology, Male, Middle Aged, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care statistics & numerical data, Prevalence, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Treatment Outcome, Gemcitabine, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Deoxycytidine analogs & derivatives, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Polymorphism, Single Nucleotide genetics
- Abstract
Objective: The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)., Methods: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods., Results: The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival., Conclusions: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.
- Published
- 2013
- Full Text
- View/download PDF